Susquehanna Fundamental Investments LLC Buys New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Susquehanna Fundamental Investments LLC purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 254,845 shares of the biopharmaceutical company's stock, valued at approximately $1,221,000. Susquehanna Fundamental Investments LLC owned approximately 0.44% of Vanda Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth approximately $69,000. Zacks Investment Management bought a new position in Vanda Pharmaceuticals in the 4th quarter valued at approximately $74,000. Price T Rowe Associates Inc. MD lifted its position in Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 3,370 shares in the last quarter. SG Americas Securities LLC boosted its stake in Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 5,459 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Vanda Pharmaceuticals by 28.0% in the 4th quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 7,339 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on VNDA. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating on the stock.

Insider Activity

In related news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the transaction, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. This trade represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 32,000 shares of company stock valued at $151,180 in the last 90 days. Company insiders own 8.90% of the company's stock.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock traded down $0.24 on Tuesday, reaching $4.36. The stock had a trading volume of 293,666 shares, compared to its average volume of 756,911. The company has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $4.67. The stock has a market cap of $256.66 million, a P/E ratio of -13.61 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 1 year low of $3.85 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.